Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference

Associated Press

15-04-2025

Data from Phase 2 Trial VGX-001-012 of Mizagliflozin in Post Bariatric Hypoglycemia will be Presented
RALEIGH, NC / ACCESS Newswire / April 15, 2025 / Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it will present phase 2 clinical data from Study VGX-001-012 (NCT05721729) at the Endocrine Society (ENDO) 2025 Annual Conference highlighting Mizagliflozin's effect on hypoglycemic events and relevant pharmacodynamic indicators in patients diagnosed with post bariatric hypoglycemia (PBH). Vogenx will present the data during an oral presentation during the ENDO 2025 Conference which will take place July 12-15, 2025 in San Francisco, California.
Abstract Number: 3890
Title: Efficacy and Safety of the SGLT1 Inhibitor Mizagliflozin in Patients with Post-Bariatric Hypoglycemia
Presentation Type: Oral
Session Date & Time: Saturday Jul 12, 2025; 1:45 PM - 3:15 PM
Location: Moscone Convention Center, 747 Howard St, San Francisco, CA 94103
Additional details will be made available prior to the Conference.
About Mizagliflozin
Mizagliflozin is an investigational first-in-class, oral, small molecule drug candidate that reduces postprandial glucose absorption, secretion of insulin, and secretion of gastric inhibitory peptide, also known as glucose-dependent insulinotropic peptide (GIP). The molecule is being developed by Vogenx for the treatment of PBH and gastroparesis, both debilitating diseases with high unmet medical need in underserved patient populations. Mizagliflozin has shown statistically significant reductions in Level 3 hypoglycemia events, postprandial glucose absorption as well as secretion of insulin and GIP in patients diagnosed with PBH.
About Post-Bariatric Hypoglycemia
PBH is an increasingly recognized chronic side effect of bariatric surgeries that are commonly performed as a treatment for obesity and related comorbidities. Neuroglycopenic symptoms can include shakiness, dizziness, confusion, sweating and loss of consciousness. These symptoms can debilitate with a significant negative impact on quality of life, can dangerously impair normal day-to-day activities and can be life-threatening.
Bariatric surgery has proven to be the most effective treatment for severe obesity, leading to significant improvements in body mass index and obesity-related co-morbidities. It is estimated that over 9% of the U.S. population has a body mass index above 40 which is considered severely obese. With over 250,000 bariatric surgery procedures performed per year in the United States, postoperative prevalence of hypoglycemia symptoms in bariatric surgery patients is thought to be as high as 38.5%. There are currently no therapeutics approved by the FDA for the treatment of PBH.
About Vogenx, Inc.
Vogenx, Inc. is a clinical-stage life science company based in Raleigh, North Carolina. Vogenx is focused on developing novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases with high unmet medical need. The company is developing Mizagliflozin for post bariatric hypoglycemia and gastroparesis. For more information about Vogenx, please visit https://vogenx.com.
For more information:
+1 919.659.5677
[email protected]
SOURCE: Vogenx, Inc.
press release